Clinical Trial Update: Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial assessing AVP-923 for central neuropathic pain in multiple sclerosis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Neuropathic Pain
• Multiple Sclerosis

Drugs mentioned

• AVP-923

Snippet

Sponsor: Avanir Pharmaceuticals | Conditions: Central Neuropathic Pain, Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2021-11-22